Venus Remedies has launched its drug, Elores, in Oman’s pharmaceutical market. Designed to combat infections caused by multidrug-resistant bacteria, Elores is proven to be effective against challenges. The launch aims to address the concern of antimicrobial resistance globally.
Oman’s antibacterial market holds a value of $7.5 million, with Elores aiming to capture 0.5 percent of this segment ($0.375 million) by 2025. This launch targets high rates of ESBL and MBL-producing gram-negative infections, which are prevalent in Oman.
Aditi K Chaudhary, President, International Business, Venus Remedies, said, “With Elores launched in Oman, we are now targeting the $237-million antibiotic market in the GCC region, out of which 54 percent accounts for ESBL and MBL resistance segment.”
Elores offers an approach in tackling antibiotic resistance, with clinical studies showcasing outcomes. The antibiotic is capable of reducing treatment time and costs while combating drug-resistant genes. Its potential has been acknowledged by global experts and institutions.
With Venus Remedies‘ approach, Elores’ reach is expanding to various countries, including Colombia, Dominican Republic, Ethiopia, Guatemala, Myanmar, Saudi Arabia, Tanzania, and more. The company is eyeing markets like Kenya, Philippines, Kuwait, and Qatar.